|
Combination Therapy to Treat Pediatric Brain Tumor
Application
Combination therapy (inhibition of STAT3 and YB-1) to treat medulloblastoma.
Key Benefits
Drug combination targets cancer stem cells.
Increased apoptosis of cancer cells compared to current chemotherapeutic agents.
Market Summary
Medulloblastoma (MB) is the most common cancerous brain tumor that affects children and survival rates...
Published: 1/28/2020
Inventor(s): Tobey MacDonald, Anna Kenney, James Felker, Abhinav Dey
|
|
Reprogramming Human Urine Stem Cells into Vascular Tissue
Application
System to generate vascular progenitor cells within naturally constructed (or formed) biomatrices from urine cells.
Key Benefits
Nearly limitless supply of source cells.
Non-invasive method for harvesting source cells.
Efficient endothelial cell generation with fewer steps and faster generation time than current standard for differentiating...
Published: 1/23/2020
Inventor(s): Young-Sup Yoon, Young-Doug Sohn, Sang-Ho Lee
|
|
Eradication of Pneumonococcal Carriage with Sodium Deoxycolate
Application
Antibiotic use of sodium deoxycholate for preventing colonization with Streptococcus pneumoniae and treating pneumococcal infection.
Key Benefits
Effective against antibiotic-resistant pneumococcus.
FDA-approved for use in humans.
Safety already demonstrated in FDA trials for subcutaneous injection to dissolve fat deposits in humans.
Market...
Published: 1/22/2020
Inventor(s): Jorge Vidal
|
|
Small Molecule for Treatment-Resistant Lung Cancer
Application
Small molecule agonist for treating cancers involving KRAS mutations.
Key Benefits
Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC).
Selective for mutant KRAS lung cancer cells over normal cells.
Non-toxic to normal cells.
Market Summary
Lung cancer is the leading cause of cancer death in the US. Lung cancer...
Published: 1/14/2020
Inventor(s): Xingming Deng
|
|
Subunit-Selective NMDAR Antagonists for Treatment of Neurological Disorders
Application
GluN2C/2D selective inhibitors that modulate N-methyl-D-aspartic acid receptors (NMDAR) in a subunit-selective manner for treatment of neurological disorders.
Key Benefits
Specifically targets NMDARs that contain the GluN2C/2D subunit.
Higher potency and efficacy compared to previously reported GluN2C/2D-selective modulators.
Market...
Published: 1/10/2020
Inventor(s): Yao Jing, Stephen Traynelis, Dennis Liotta
|
|
Small Molecules to Promote Bone Growth
Application
Small molecule sclerostin-inhibitors to enhance the canonical Wnt pathways and promote BMP-induced osteoblast differentiation.
Key Benefits
Repurposing opportunities of FDA approved drugs.
Lower cost compared to currently available monoclonal antibody or recombinant protein therapies.
Stable compounds with established safety profiles...
Published: 12/3/2019
Inventor(s): Scott Boden, Steven Presciutti, Sreedhara Sangadala
|
|
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application
Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries.
Key Benefits
Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries.
Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 12/2/2019
Inventor(s): Ahsan Husain, Nawazish Naqvi
|
|
Antibacterial Treatment for Gum Disease
Application
Small molecules that inhibit oral bacteria growth to treat gum disease and prevent tooth decay.
Key Benefits
Inhibits S. mutans biofilm formation.
Reduces the number of bacteria by working in a bactericidal, as opposed to bacteriostatic, manner.
Market Summary
Periodontitis is a gum infection in which gums become inflamed due to...
Published: 12/2/2019
Inventor(s): William (Bill) Wuest, Amy Solinski, Marisa Kozlowski, Young Eun Lee, Thomas Paniak, Cristian Ochoa
|
|
Combination Therapy Using Small Molecule Conjugation to Reovirus for TNBC Treatment
ApplicationSmall molecule inhibitor doxorubicin hydrochloride (Dox) conjugated to reovirus for targeted combination therapy of triple-negative breast cancer (TNBC).Key BenefitsTargeted treatment that directly infects and kills breast cancer cells.Increased cytopathicity, cytotoxicity and faster induction of cell death than virus alone.Enhanced selective...
Published: 10/11/2019
Inventor(s): Bernardo Mainou, Roxana Rodriguez, Angela Berger
|
|
Hybrid Proton-Photon Inverse Optimization to Deliver Radiation Therapy
Application
Hybrid proton-photon inverse optimization method that synergizes proton and photon therapy with improved total optimization objectives for robust cancer treatment delivery.
Key Benefits
Improved planning target volume coverage and organ at risk sparing.
Reduced overall optimization values.
Less expensive treatment than proton therapy...
Published: 10/11/2019
Inventor(s): Hao Gao
|
Emory UniversityOffice of Technology Transfer